Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tobevibart + elebsiran + tenofovir disoproxil fumarate
- Development stage
- Phase 2
- Lead developer
- Vir Biotechnology
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (tobevibart And Elebsiran), Oral (tenofovir Disoproxil Fumarate)
01
Overview
The combination of **tobevibart**, **elebsiran**, and **tenofovir disoproxil fumarate** is an investigational therapeutic regimen targeting chronic hepatitis delta virus (HDV) infection, typically in patients co-infected with hepatitis B virus (HBV). Tobevibart is a broadly neutralizing monoclonal antibody that binds to the antigenic loop of hepatitis B surface antigen (HBsAg), blocking viral entry into hepatocytes and neutralizing both HBV and HDV. Elebsiran is a small interfering RNA (siRNA) that targets a conserved region of the HBV genome, suppressing expression of HBsAg and reducing viral replication. Tenofovir disoproxil fumarate is a nucleotide analogue reverse transcriptase inhibitor, inhibiting HBV replication. The triple therapy is designed to suppress viral replication, promote normalization of liver enzymes, reduce HBsAg levels, and potentially achieve functional cure of HBV/HDV infection. Preclinical and clinical studies support additive antiviral effects of tobevibart and elebsiran, and tenofovir is used as background therapy for HBV suppression[1][2][3][4][6][7].
- Brand names
- none known for this triple combination; individual drugs may have brand names (e.g., tenofovir disoproxil fumarate is sold as "Viread")
02
Targets
HBV RNA (Hepatitis B virus RNA)HBV Pol (Hepatitis B virus polymerase)HBsAg (Hepatitis B surface antigen)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on tobevibart + elebsiran + tenofovir disoproxil fumarate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tobevibart + elebsiran + tenofovir disoproxil fumarate.